C4 Therapeutics Inc.

10/30/2024 | Press release | Distributed by Public on 10/30/2024 12:10

TPD Summit - Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946, a BRAF V600 Mutant Degrader, for Solid Tumors

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.